TITLE
[Ovarian suppression with Diane 35/50]. Die ovarielle Suppression unter
Diane 35/50.
AUTHOR
Erdmann D; Schindler EM; Schindler AE
ORGANISATION
Abteilung Gynakologie, Universitatsklinikum Essen.
SOURCE
Geburtshilfe Frauenheilkd 1994 Nov; 54 (11): 627-33
LANGUAGE OF PUBLICATION
German (1350-)
ABSTRACT
In this study, hormone profiles were studied using Diane 35 and Diane 50
before and after treatment for 4-25 months. A comparison of the hormone
profiles with Diane 35 or Diane 50 should investigate, if both preparations
induce complete ovarian suppression, independent of the given dose of ethinyl
oestradiol. 43 patients were treated with Diane 35 and 15 women with Diane 50
over a different lengths of time -- up to a period of 25 cycles. Parallel to
the determination of the hormone profiles (luteinising hormone [LH], follicle
stimulating hormone [FSH], prolactin, oestrone [E1], oestradiol [E2],
progesterone, total testosterone [T. T.], free testosterone [F. T.],
dehydroepiandrosterone-sulfate [DHEA-S], delta-4-androstenedione [A.] and sex
hormone binding globulin [SHBG]), observations on the androgen symptoms before
treatment and their course during therapy were made. Moreover, the ratios of
LH/FSH and E1/E2 as well as the androgenic index, the ratio of total
testosterone/SHBG were determined as control of treatment effects. The most
important hormonal changes, which had been observed during a period up to two
years are the following: -- LH and FSH suppression -- prolactin with increasing
tendency -- decrease of the total androgens and free testosterone -- decrease
of the oestrogens E1, E2 -- increase of SHBG. The confirmation of the efficacy
of the anti-androgen/oestrogen combination was reflected by the decline of the
androgenic index in all groups. Acne and seborrhoe improved after 3-4 cycles;
alopecia after 8-9 cycles and hirsutism diminished after 3 cycles of treatment.
In spite of different doses of the combined preparations with 2 mg
cyproteronacetate and 0.035 or 0.050 mg ethinyloestradiol, no difference in
ovarian suppression as well clinical effects could be found. (AUTHOR)
MJTR: Androgen Antagonists AD. Cyproterone
Acetate AD. Ethinyl Estradiol AD. Sex Hormones BL.
MNTR: Adult. Androgen Antagonists AE.
Comparative Study. Cyproterone Acetate AE. Dose-Response Relationship, Drug.
Drug Combinations. English Abstract. Ethinyl Estradiol AE. Female. Human.
Menstrual Cycle BL. Menstrual Cycle DE. Treatment Outcome. CLINICAL TRIAL.
JOURNAL ARTICLE. RANDOMIZED CONTROLLED TRIAL
RNUM: 0 (Androgen Antagonists); 0 (Drug
Combinations); 0 (Sex Hormones); 427-51-0 (Cyproterone Acetate); 57-63-6
(Ethinyl Estradiol); 60528-19-0 (Diane)
GEOT: GERMANY
IDEN: ISSN: 0016-5751. JOURNAL-CODE: FK5.
ENTRY-DATE: 960926. JOURNAL-SUBSET: M. IM-DATE: 9611.